Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06530186

Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters

LiviWell has developed a product designed for postcoital semen absorption. Previous studies have demonstrated the product rapidly absorbs semen, and leads to less symptoms of postcoital vaginal microbiome disruption such as vaginal odor and discharge. This study will investigate the study device, Livi, in a broader clinical setting.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Garden State Urology

Mountain Lakes, New Jersey, 07046, United States

Location contact

Cathy Smith, MA

CONTACT

[email protected]

973-537-5557

Michael Ingber, MD

PRINCIPAL_INVESTIGATOR

About this study

LiviWell's consumer hygiene device is a post-coital vaginal insert called "Livi". Livi is comprised of an applicator, with a medical-grade polyurethane foam and retrieval string. It is designed to be inserted into the vagina after intercourse to absorb semen deposited into the vaginal canal. The result is a decrease in discharge/dripping and vaginal odor. The investigators also believe the device will lower vaginal pH, as the typical premenopausal vaginal pH is acidic (pH ~4), and semen has an alkaline pH (~8). The resulting pH imbalance in sexually-active women not using male condoms had been shown to lead to vaginal odor, dripping, discomfort. Furthermore, the risk of bacterial vaginosis (BV) is higher in women who are sexually active and not using male condoms. The investigators have additional studies planned to evaluate if the product lowers the risk of BV.

The current study will be used to validate user needs requirements for the study device, understand pH changes after insertion, and evaluate change in symptoms of vaginal odor, discharge/dripping, and discomfort, common symptoms of vaginal microbiome disruption and bacterial vaginosis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over 18 (for pH subset, 18-45)
  • Sexually-active with biological men
  • Willing and able to use product
  • Resides in continental USA
  • Understands, reads, writes, and speaks English

Exclusion criteria

  • Currently Pregnant or are trying to conceive
  • Unable to use device due to poor motor function
  • Unable to sign informed consent

Treatment and study plan

LiviWell Postcoital Vaginal Insert

Device

subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.

Other names: Livi

Primary outcomes

  1. User Experience Questionnaire

    Time frame: 24 hours

    Validation of User Needs Requirements as well as patient experience

Secondary outcomes

  1. change in vaginal pH

    Time frame: 2-6 hours, and 10-14 hours after use

    change in vaginal pH before and after using Livi, and before and after NOT using Livi

Sponsors and collaborators

Lead sponsor

Atlantic Health System

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Jul 31, 2024
Registry last updated
Jul 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.